Breast Cancer Drugs Market Outlook 2031
The Breast Cancer Drugs Market size was USD 26.4 Billion in 2022 and is likely to reach USD 54.56 Billion by 2031, expanding at a CAGR of 8.4% during 2023–2031. The growth of the market is attributed to the increasing prevalence of diseases coupled with emerging novel therapies.
For effective management of breast cancer the early detection is a key factor. Early detection of disease gives desired outcomes such as increasing number of treatment options, raising survival rate, and improves quality of life.
- Based on an article 2018 Research Fast Facts was published by Susan G. Komen, stated that regular screening and early detection reduces the death rate by 30%.
Based on International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, in women, breast cancer is fifth major cause responsible for deaths, which is around 626,989 deaths each year. As per the American Cancer Society, in 2018, around 266,000 new cases were diagnosed in women in U.S. Moreover, aging is one of the highest risk factors.
As per Cancer Treatment Centers of America, breast cancer in women above 60 years of age are possibly diagnosed and only around 10-12% of cases were found in women less than 45 years of age. Huge presence of disease along with expiry of patent are key factors responsible for increasing investment in R&D of novel products.
The R&D expenditure from companies such as Merck & Co. Inc., Pfizer, Sanofi, Johnson & Johnson Services Inc., AbbVie Inc., GlaxoSmithKline plc., and Celgene Corporation are rising significantly, but sudden fall is noted for AstraZeneca, Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd, Novartis Company.
Breast Cancer Drugs Market Trends, Drivers, Restraints, and Opportunities
- Growing prevalence of disease is major factor responsible for propelling the market growth over the forecast period.
- Increasing concern for effective treatment and management, and rising investment of key players in research and innovation are anticipated to drive the market growth.
- Growing number of pipelined drugs and rising research and development of novel drugs are projected to fuel the growth of the market.
- Environmental factors, new generation treatments and bio-similar versions, changing lifestyle, physical inactivity, and hormonal changes are some factors responsible for driving the market expansion.
- Rising new treatment methods and therapies is expected to boost the market growth over the forecast period.
- Stringent regulations, expiry of the patented drugs, and prolonged therapies degrading the health are anticipated to hamper the market growth.
- Lack of accessibility of medical attention and less awareness about healthcare among people are projected to impede the market expansion.
Scope of The Breast Cancer Drugs Market Outlook Report
The report on the global breast cancer drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Breast Cancer Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2022
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023–2031
|
Segmentation
|
Types (Hormonal Receptors, Mitotic Inhibitors, HER2 Inhibitors, Anti-metabolites, CDK 4/6 Inhibitors, and Aromatase Inhibitors)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
F. Hoffmann-La Roche Ltd.; Novartis AG; AbbVie, Inc.; AstraZeneca; Eli Lilly and Company; Celgene Corporation; Biocon; Merck & Co., Inc.; Genzyme Corporation; Janssen Global services LLC; MacroGenics, Inc.; Celldex Therapeutics; Onyx Pharmaceuticals Inc.; and BioNumerik Pharmaceuticals, Inc.
|
Breast Cancer Drugs Market Segment Insights
HER2 inhibitors segment is projected to hold a major market share
Based on types, the breast cancer drugs market is segmented into hormonal receptors, mitotic inhibitors, HER2 inhibitors, anti-metabolites, CDK 4/6 inhibitors, and aromatase inhibitors. The HER2 inhibitors segment is expected to hold a key share of the market during the forecast period owing to rising incidence of HER2 positive breast cancer.
As per article published in 2013, by F. Hoffman La Roche Ltd., one out of five women were diagnosed the breast tumor would have HER2 positive cancer. In addition, demand is rapidly increasing from emerging countries such as Asia Pacific and Latin America which is projected to propel the segment growth over the forecast period.
However, the CDK 4/6 inhibitor segment is anticipated to expand at a rapid pace during the forecast period. These drugs are anticipated to increase the patient’s survival rate having metastatic breast cancer.
North America is anticipated to dominate the market
On the basis of regions, the breast cancer drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to rising awareness among people and increasing presence of established R&D infrastructure.
Furthermore, presence of major market players such as Merck & Co., Inc.; AbbVie, Inc.; Pfizer, Inc.; and Celgene Corporation in the region is projected to boost the regional market growth. On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years. Globally, demand of drugs is increasing which results in growing manufacturing and R&D facilities by manufacturers in this region.
Initiatives taken by several organizations to educate people, raise funds, and create awareness about disease is expected to fuel the regional market growth.
Segments
The global breast cancer drugs market has been segmented on the basis of
Types
- Hormonal Receptors
- Mitotic Inhibitors
- HER2 Inhibitors
- Anti-metabolites
- CDK 4/6 Inhibitors
- Aromatase Inhibitors
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- AbbVie, Inc.
- AstraZeneca
- Eli Lilly and Company
- Celgene Corporation
- Biocon
- Merck & Co., Inc.
- Genzyme Corporation
- Janssen Global services LLC
- MacroGenics, Inc.
- Celldex Therapeutics
- Onyx Pharmaceuticals Inc.
- BioNumerik Pharmaceuticals, Inc.
Competitive Landscape
Key players competing in the breast cancer drugs market are F. Hoffmann-La Roche Ltd.; Novartis AG; AbbVie, Inc.; AstraZeneca; Eli Lilly and Company; Celgene Corporation; Biocon; Merck & Co., Inc.; Genzyme Corporation; Janssen Global services LLC; MacroGenics, Inc.; Celldex Therapeutics; Onyx Pharmaceuticals Inc.; and BioNumerik Pharmaceuticals, Inc.
Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, in March 2017, Kisqali was approved by the Food and Drug Administration (FDA) for HR+/HER2 which was the first-line treatment for metastatic breast cancer along with an aromatase inhibitor.